Information Travel Wikepedia

Thuto e Ncha e Fumana Lefu la Kankere ea Matsoele Lefatšeng Lohle le Eketsehile

ngotsoeng ke mohlophisi

Maemo a mofets'e a ntse a eketseha, ho latela phuputso e ncha e bapisang palo ea batho ba tšoeroeng ke mofetše lefatšeng ka bophara ka 2010 le 2019. Har'a lintlha, bafuputsi ba pakile hore palo ea mofetše lefatšeng ka bophara e nyolohile ka + 26% le hore mofetše oa matsoele e ne e le sesosa se ka sehloohong sa mofets'e. -Lilemo tsa bophelo tse amanang le bokooa (DALYs), lefu, le lilemo tsa bophelo tse lahlehileng (YLLs) har'a basali lefatšeng ka bophara ka 2019.

Print Friendly, PDF & Email

Ho latela Lipatlisiso le Limmaraka, 'maraka oa lefats'e oa lithethefatsi tsa mofetše oa matsoele o lebelletsoe ho hola ho $19.49 bilione ka 2025 ho CAGR ea 7.1%. Har'a bahlahisi ba biotech ba sebetsang ho fihlela 2022 mabapi le liphekolo tse ncha tsa mofetše oa matsoele ke Oncolytics Biotech Inc., Roche Holding AG, Pfizer Inc., Incyte Corporation, le AstraZeneca PLC.

Har'a mafu a mofetše a lebisitsoeng ke Oncolytics Biotech Inc. le moemeli oa eona oa pele oa immunotherapeutic pelareorep, mofetše oa matsoele ke sepheo sa mantlha sa k'hamphani, ho latela lengolo la eona la morao-rao le eang ho beng ba liabo le lekotseng katleho ea lona ka 2021 le ho hlalosa lenaneo le tlang la 2022.

Ka har'a Lenaneo la eona la Kankere ea Matsoele ho fihlela joale, Oncolytics e bone ho pholoha habeli ho feta ho habeli ho bakuli ba mofetše oa matsoele oa metastatic HR+/HER2- ba phekoloang ka pelareorep ho IND-213 - joalo ka ha ho bonoa liphetho tsa lithuto tse fanoeng ka 2017.

Ka mor'a ho hlahloba lintlha tse eketsehileng, Oncolytics e ile ea khetha ho tsepamisa maikutlo lipakaneng tse tharo tse ka finyelloang tse behiloeng ke balaoli le balekane ba k'hamphani ea pharma, e leng se emelang mehato ea bohlokoa e lebisang thutong ea ngoliso. Sena se ne se kenyelletsa: 1. Ho tiisa hore pelareorep e sebetsa ka mokhoa oa immunotherapeutic oa ketso; 2. Ho etsa qeto ea hore na pelareorep e sebelisana le li-immune checkpoint inhibitors; le 3. Ho khetholla biomarker ho khetha bakuli ba ka 'nang ba e-ba le liphello tse molemo tsa kliniki.

Ho tloha ka Mmesa 2021, Oncolytics e hlahisitse lintlha tsa sehlopha ho tsoa boithutong ba eona ba AWARE-1, e ntseng e etsoa le Roche Holding AG (OTC:RHHBY), e bonts'ang hore k'hamphani e fihletse lipheo tse peli tsa pele tse boletsoeng ka holimo.

Hamorao ka Tšitoe ho 2021 San Antonio Breast Cancer Symposium (SABCS), Oncolytics e ile ea hlahisa tlhahiso e ntle ea ts'ireletso ho tsoa ho Teko ea eona ea IRENE Phase 2 Triple-Negative Breast Cancer e lekola polokeho le katleho ea pelareorep hammoho le anti-PD-1 checkpoint inhibitor. retifanlimab ho tsoa ho Incyte Corporation bakeng sa kalafo ea mohala oa bobeli kapa oa boraro oa bakuli ba nang le mofetše oa matsoele oa metastatic triple-negative (TNBC).

Lintlha tsa ts'ireletso tse tsoang tekong li bontšitse hore motsoako o mamelloa hantle, ho se na mathata a tšireletso a boletsoeng ho leha e le ofe oa bakuli ba ngolisitsoeng tekong nakong ea tlaleho.

Thuto ea IRENE e ntse e tsoela pele 'me e tla tsoelapele ho ngolisa bakuli Setsing sa Kankere sa Rutgers sa New Jersey le Setsi sa Kankere sa Kankere sa Ohio State.

Incyte Corporation haufinyane e fane ka ntlafatso e 'ngoe e kenyelletsang retifanlimab ea eona hammoho le mokhethoa ea ka sehloohong oa BriaCell Therapeutics' Bria-IMTTM ho SABCS. Ha e akaretsoa ntlafatsong, ho pholoha ka kakaretso ho ne ho phahame haholo ho bakuli thutong e kopantsoeng, ho fana ka maikutlo a hore ho na le phello e eketsehileng kapa ea synergistic le ho tšehetsa tsoelo-pele ea thuto. Ho latela webosaete ea BriaCell, lintlha tse ling tsa polokeho le katleho li lebelletsoe ho fihlela 2022.

Pfizer, Inc. e sa tsoa kena tumellanong ea tšebelisano ea liteko tsa tleliniki le tumellano ea phepelo le Celcuity, moo pharma giant e tla fana ka Palbociclib (Ibrance) bakeng sa ho sebelisoa thutong ea kliniki ea mohato oa 3 e etsoang ke Celcuity ntle ho tefo ho k'hamphani.

Teko ea kliniki ea mohato oa 3 e lebelletsoe ho qala halofo ea pele ea 2022 ho lekola ts'ebeliso ea pan-PI3K/mTOR inhibitor gedatolisib (PF-05212384) hammoho le palbociclib le fulvestrant bakeng sa bakuli ba nang le estrogen receptor (ER) -positive, HER2 - kankere ea matsoele e mpe e tsoetseng pele. Celcuity e tla fana ka lintlha tse ling mabapi le teko ea tleliniki kamora puisano le maikutlo a latelang ho tsoa ho FDA.

Ho elella bofelong ba 2021, AstraZeneca PLC le balekane Daiichi Sankyo ba phatlalalitse hore European Medicines Agency (EMA) e netefalitse Kopo ea eona ea Mofuta oa II bakeng sa trastuzumab deruxtecan (T-DXd; Enhertu) bakeng sa kalafo ea matsoele a tsoetseng pele, a neng a phekoloa HER2-positive pele. bakuli ba mofetše.

Ho sa le joalo, mokuli oa pele ea nang le HR+, HER2- kankere ea matsoele e sa sebetseng ea metastatic o ile a fuoa datopotamab deruxtecan (DS-1062a; dato-DXd) e le karolo ea teko ea 3 TROPION-Breast01 (NCT05104866). DXd ADC e tataisoang ke TROP2 eo hajoale e ntseng e ntlafatsoa ke Daiichi Sankyo le AstraZeneca hajoale e ntse e etsoa lipatlisiso tekong ea lefats'e ka bophara, e sa reroang, e bulehileng ka tekanyo ea 6 mg/kg ha e bapisoa le khetho ea mofuputsi ea chemotherapy.

Mokhoa o mong oa ho ntlafatsa menyetla ea toants'o ea mofets'e, ke peiso ea ho ntlafatsa ho lemoha kapele. Ho latela Setsi sa Carol Milgard Breast Center ho lemoha kapele ke senotlolo.

Roche Holding AG e sa tsoa raha liranta tse limilione tse 290 molemong oa lichelete o fetang $ 1 bilione ho bahlahisi ba biopsy ea metsi Freenome. 

Print Friendly, PDF & Email

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Leave a Comment